Wells Fargo & Company Cyclerion Therapeutics, Inc. Transaction History

Wells Fargo & Company

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.43 - $0.9 $901 - $1,886	-2,096 Reduced 88.55%	271 $0
Q4 2022 Feb 13, 2023	BUY	$0.42 - $18.8 $842 - $37,731	2,007 Added 557.5%	2,367 $1,000
Q3 2022 Nov 14, 2022	SELL	$0.58 - $18.2 $23 - $728	-40 Reduced 10.0%	360 $0
Q2 2022 Aug 12, 2022	BUY	$0.47 - $1.29 $11 - $30	24 Added 6.38%	400 $0
Q1 2022 May 16, 2022	BUY	$0.96 - $1.78 $1 - $3	2 Added 0.53%	376 $0
Q4 2021 Feb 14, 2022	SELL	$1.56 - $2.99 $9 - $17	-6 Reduced 1.58%	374 $0
Q3 2021 Nov 15, 2021	BUY	$2.73 - $4.13 $177 - $268	65 Added 20.63%	380 $1,000
Q2 2021 Aug 16, 2021	SELL	$2.18 - $4.29 $16,334 - $32,144	-7,493 Reduced 95.97%	315 $1,000
Q1 2021 May 13, 2021	SELL	$2.69 - $5.12 $114,900 - $218,695	-42,714 Reduced 84.55%	7,808 $21,000
Q4 2020 Feb 09, 2021	BUY	$2.25 - $7.12 $49,792 - $157,565	22,130 Added 77.94%	50,522 $154,000
Q3 2020 Nov 05, 2020	SELL	$3.46 - $8.39 $21,732 - $52,697	-6,281 Reduced 18.11%	28,392 $173,000
Q2 2020 Aug 13, 2020	SELL	$2.37 - $7.14 $47,945 - $144,442	-20,230 Reduced 36.85%	34,673 $205,000
Q1 2020 May 14, 2020	BUY	$2.46 - $5.84 $135,061 - $320,633	54,903 New	54,903 $145,000

293K

Ticker CYCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,479,800
Market Cap $139M
Description
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.